| 09.05 22:19 | dpa-AFX: Nektar Therapeutics Q1 Loss Drops In Line With Estimates |
| 09.05 22:17 | dpa-AFX: *NEKTAR THERAPEUTICS Q1 REVENUE $21.64 MLN VS. $21.59 MLN LAST YEAR |
| 09.05 22:17 | dpa-AFX: *NEKTAR THERAPEUTICS Q1 LOSS/SHARE $0.19 VS. LOSS $0.73 YEAR AGO |
| 05.03 15:02 | dpa-AFX: *NEKTAR INITIATES PHASE 2B STUDY OF REZPEGALDESLEUKIN IN SEVERE ALOPECIA AREATA |
| 04.03 22:18 | dpa-AFX: Nektar Therapeutics Q4 Loss decreases, but misses estimates |
| 04.03 22:17 | dpa-AFX: *NEKTAR THERAPEUTICS Q4 NET LOSS $42.08 MLN VS. LOSS $59..69 MLN PRIOR YEAR |
| 04.03 22:17 | dpa-AFX: *NEKTAR THERAPEUTICS Q4 REVENUE $23.89 MLN VS. $22.02 MLN LAST YEAR |
| 04.03 22:17 | dpa-AFX: *NEKTAR THERAPEUTICS Q4 LOSS/SHARE $0.22 VS. LOSS $0.32 YEAR AGO |
| 04.03 21:04 | dpa-AFX: Nektar Therapeutics Q4 23 Earnings Conference Call At 5:00 PM ET |
| 04.03 15:02 | dpa-AFX: Nektar Therapeutics Announces $30 Mln Private Placement Financing With TCGX; Stock Up In Premarket |
| 04.03 14:31 | dpa-AFX: *NEKTAR THERAPEUTICS ANNOUNCES $30 MLN PRIVATE PLACEMENT FINANCING WITH TCGX |
| 07.11 22:22 | dpa-AFX: *NEKTAR THERAPEUTICS Q3 REVENUES $24.14 MLN VS. $23.63 MLN LAST YEAR |
| 07.11 22:22 | dpa-AFX: *NEKTAR THERAPEUTICS Q3 LOSS/SHARE $0.24 VS. LOSS $0.31 YEAR AGO |
| 07.11 22:18 | dpa-AFX: Nektar Therapeutics Q3 Loss decreases, but misses estimates |
| 07.11 21:00 | dpa-AFX: Nektar Therapeutics Q3 23 Earnings Conference Call At 5:00 PM ET |
| 27.09 15:48 | dpa-AFX: Nektar, Cellular Biomedicine Enter New Clinical Study Collaboration |
| 27.09 15:02 | dpa-AFX: *NEKTAR,CELLULAR BIOMEDICINE TO EVALUATE NKTR-255 IN COMBINATION WITH C-TIL051 IN ADVANCED NON-SMALL CELL LUNG CANCER |
| 13.09 15:19 | dpa-AFX: Nektar Therapeutics Reports Promising Data From Phase 1b Study Of Rezpegaldesleukin |
| 13.09 15:02 | dpa-AFX: *NEKTAR ANNOUNCES PROMISING NEW DATA FROM PHASE 1B STUDY OF REZPEGALDESLEUKIN IN ATOPIC DERMATITIS |
| 13.09 15:02 | dpa-AFX: *NEKTAR ANNOUNCES PROMISING NEW DATA FROM PHASE 1B STUDY OF REZPEGALDESLEUKIN IN ATOPIC DERMATITIS |
|
|
